Serotonin pathway and genetic variant linked to faster mitral valve disease progression
Columbia University researchers report that a specific genetic variant may accelerate heart valve damage in people with degenerative mitral regurgitation who also take SSRI antidepressants.
Researchers at Columbia University have published findings suggesting that serotonin — a neurotransmitter principally associated with mood regulation — may also influence the progression of degenerative mitral regurgitation (DMR), a common form of heart valve disease. The study, reported by ScienceDaily on 12 July 2026, identifies an interaction between SSRI antidepressant use and a specific genetic variant that the researchers associate with accelerated valve deterioration and potentially earlier need for surgical intervention.
DMR occurs when the mitral valve leaflets degenerate and allow blood to leak backwards into the left atrium. Serotonin has previously been implicated in valvular fibrosis in other contexts — for example, in carcinoid heart disease — but its role in the more common degenerative form has been less well characterised. The Columbia team's work adds a genetic dimension to this pharmacological relationship, suggesting that individual genetic background may modulate how serotonin signalling affects valve tissue.
The findings are based on observational data and require replication in larger, prospective cohorts before their implications for clinical management can be fully assessed. Published guidance from relevant cardiology and genetics bodies would need to be consulted regarding any clinical considerations. This research is nonetheless of interest to cardiovascular geneticists, clinical researchers studying gene–drug interactions, and genetic counsellors working in familial cardiac disease contexts.
The specific variant and full methodological details were not available in the feed summary; readers are directed to the primary publication for the complete dataset and statistical analysis.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Scientists at Columbia University in the United States have published research suggesting that serotonin — a chemical in the body often linked to mood — may also affect how quickly a type of heart valve disease called degenerative mitral regurgitation gets worse. The researchers found that people who carry a particular genetic variant and also take a type of antidepressant called SSRIs may experience more rapid valve damage, potentially needing surgery earlier than those without that variant.
This is early-stage research based on observational data, and scientists say more studies are needed before drawing firm conclusions. The research helps scientists better understand how genes, medicines, and the heart may interact — which could inform future research into this condition.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-07-12Columbia scientists discover surprising link between serotonin and heart valve disease